Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT02046616
- Locations
- π©π°
Aalborg Universitetshospital Nord, Reumatologisk Afdeling, Alborg, Denmark
π©π°Gentofte Hospital, Medicinsk Afd. C, Klinik for Gigt- og Rygsygdomme, Hellerup, Denmark
π©π°Glostrup Hospital, Reumatologisk Afdeling, Ambulatoriet, Glostrup, Denmark
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 162
- Registration Number
- NCT02046603
- Locations
- π¬π§
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
π¬π§Royal Sussex County Hospital; Clinical Investigation Research Unit, Brighton, United Kingdom
π¬π§University Hospital of Wales; Dept of Rhematology, Cardiff, United Kingdom
An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)
- Conditions
- Anemia
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 815
- Registration Number
- NCT02042833
Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.
- Conditions
- Healthy Volunteer, Muscular Atrophy, Spinal
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02044029
A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 128
- Registration Number
- NCT02040935
- Locations
- π³π±
Haga Ziekenhuis, Den Haag, Netherlands
π³π±Tergooiziekenhuizen, loc. Hilversum, Hilversum, Netherlands
π³π±Zuyderland ziekenhuis locatie Geleen, Sittard-Geleen, Netherlands
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis NaΓ―ve to RoActemra/Actemra Treatment
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT02031471
The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: 4 mg/kg Onartuzumab (MetMAb)Drug: 15 mg/kg Onartuzumab (MetMAb)Drug: 30 mg/kg Onartuzumab (MetMAb)
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT02031731
- Locations
- π¨π³
Sun Yet-sen University Cancer Center, Guangzhou, China
π¨π³the First Hospital of Jilin University, Changchun, China
π¨π³Beijing Cancer Hospital, Beijing, China
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 530
- Registration Number
- NCT02031744
- Locations
- π¨π³
Southwest Hospital , Third Military Medical University, Chongqing, China
π¨π³Harbin Medical University Cancer Hospital, Harbin, China
π¨π³Jilin Cancer Hospital, Changchun, China
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 667
- Registration Number
- NCT02031458
- Locations
- πΊπΈ
Angeles Clinic & Rsch Inst, Los Angeles, California, United States
πΊπΈEmory Uni - Winship Cancer Center; Hematology/Oncology, Atlanta, Georgia, United States
πΊπΈThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
- Conditions
- Neuromyelitis Optica (NMO)NMO Spectrum Disorder (NMOSD)
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT02028884
- Locations
- π«π·
Hopital de Hautepierre CHRU de Strasbourg, Strasbourg, France
π©πͺNeuroCure Clinical Research Center (NCRC), Berlin, Germany
π΅π±M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM, Katowice, Poland